343 related articles for article (PubMed ID: 16465545)
21. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
Guo F; Letrent SP; Sharma A
Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
[TBL] [Abstract][Full Text] [Related]
22. A population model of epirubicin pharmacokinetics and application to dosage guidelines.
Ralph LD; Thomson AH; Dobbs NA; Twelves C
Cancer Chemother Pharmacol; 2003 Jul; 52(1):34-40. PubMed ID: 12764671
[TBL] [Abstract][Full Text] [Related]
23. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
24. A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1).
Lindman H; Andersson M; Ahlgren J; Balslev E; Sverrisdottir A; Holmberg SB; Bengtsson NO; Jacobsen EH; Jensen AB; Hansen J; Tuxen MK; Malmberg L; Villman K; Anderson H; Ejlertsen B; Bergh J; Blomqvist C;
Eur J Cancer; 2018 May; 94():79-86. PubMed ID: 29547834
[TBL] [Abstract][Full Text] [Related]
25. Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer.
Saji S; Toi M; Morita S; Iwata H; Ito Y; Ohno S; Kobayashi T; Hozumi Y; Sakamoto J
Oncology; 2007; 72(5-6):330-7. PubMed ID: 18187954
[TBL] [Abstract][Full Text] [Related]
26. Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation.
Schröder CP; Wisman GB; de Jong S; van der Graaf WT; Ruiters MH; Mulder NH; de Leij LF; van der Zee AG; de Vries EG
Br J Cancer; 2001 May; 84(10):1348-53. PubMed ID: 11355946
[TBL] [Abstract][Full Text] [Related]
27. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
Variol P; Nguyen L; Tranchand B; Puozzo C
Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
[TBL] [Abstract][Full Text] [Related]
28. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
De Jonge ME; Mathôt RA; Van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2002 Sep; 50(3):251-5. PubMed ID: 12203108
[TBL] [Abstract][Full Text] [Related]
29. Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats.
Jonsson E; Friberg LE; Karlsson MO; Hassan SB; Freijs A; Hansen K; Larsson R
Cancer Chemother Pharmacol; 2000; 46(6):493-500. PubMed ID: 11138463
[TBL] [Abstract][Full Text] [Related]
30. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetics of oral busulfan in children.
Schiltmeyer B; Klingebiel T; Schwab M; Mürdter TE; Ritter CA; Jenke A; Ehninger G; Gruhn B; Würthwein G; Boos J; Hempel G
Cancer Chemother Pharmacol; 2003 Sep; 52(3):209-16. PubMed ID: 12811512
[TBL] [Abstract][Full Text] [Related]
32. Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information.
Wallin JE; Friberg LE; Karlsson MO
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):234-42. PubMed ID: 20050841
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
34. Dehydropyrimidine dehydrogenase deficiency in a cancer patient undergoing 5-fluorouracil chemotherapy.
Schneider HB; Becker H
Anticancer Res; 2004; 24(2C):1091-2. PubMed ID: 15154628
[TBL] [Abstract][Full Text] [Related]
35. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.
Nguyen L; Leger F; Lennon S; Puozzo C
Cancer Chemother Pharmacol; 2006 Jan; 57(2):191-8. PubMed ID: 16133536
[TBL] [Abstract][Full Text] [Related]
36. [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
Conti F; Carpano S; Sergi D; Di Lauro L; Amodio A; Vici P; Abbate MI; Ferranti FR; Viola G; Botti C; Foggi P; Sperduti I; Lopez M
Clin Ter; 2007; 158(4):331-41. PubMed ID: 17953285
[TBL] [Abstract][Full Text] [Related]
37. Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy.
Boidot R; Vegran F; Lizard-Nacol S
Int J Mol Med; 2009 Feb; 23(2):285-91. PubMed ID: 19148555
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer.
Fernandes BJ; Silva Cde M; Andrade JM; Matthes Ado C; Coelho EB; Lanchote VL
Cancer Chemother Pharmacol; 2011 Oct; 68(4):897-904. PubMed ID: 21290248
[TBL] [Abstract][Full Text] [Related]
39. Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy.
Beneton M; Chapet S; Blasco H; Giraudeau B; Boisdron-Celle M; Deporte-Fety R; Denis F; Narcisso B; Calais G; Le Guellec C
Br J Clin Pharmacol; 2007 Nov; 64(5):613-21. PubMed ID: 17578483
[TBL] [Abstract][Full Text] [Related]
40. Good response to paclitaxel predicts high rates of pathologic complete response for breast cancer patients treated preoperatively with paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide.
Kim SJ; Taguchi T; Shimazu K; Tanji Y; Tamaki Y; Noguchi S
Oncology; 2009; 77(2):134-9. PubMed ID: 19628951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
